Wells Fargo analyst Brandon Couillard added Exact Sciences (EXAS) to the firm’s Q4 2025 Tactical Ideas List. The firm says valuation is compelling and Wells sees positive catalysts near-term, including upside to Q3 results driven by multiple Screening tailwinds, along with V2 subset data read-out for Freenome’s CRC blood test. The firm has an Overweight rating on the name with a price target of $68 on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences Receives Buy Rating from Bruce Jackson Amid Promising MCED Test Launch and Strong Financial Projections
- Craig-Hallum healthcare/pharma analysts hold analyst/industry conference call
- Exact Sciences management to meet with Craig-Hallum
- Exact Sciences price target raised to $85 from $65 at Craig-Hallum
- Exact Sciences launches Cancerguard test in the U.S.